The stock of Phio Pharmaceuticals Corp (NASDAQ: PHIO) has increased by 4.84 when compared to last closing price of 0.72.Despite this, the company has seen a loss of -22.46% in its stock price over the last five trading days. PennyStocks reported 2023-12-05 that Penny stocks, defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it’s understandable why penny stocks attract interest from new traders.
Is It Worth Investing in Phio Pharmaceuticals Corp (NASDAQ: PHIO) Right Now?
The 36-month beta value for PHIO is at 1.45. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PHIO is 2.40M, and currently, shorts hold a 1.92% of that float. The average trading volume for PHIO on March 26, 2024 was 336.09K shares.
PHIO’s Market Performance
PHIO’s stock has seen a -22.46% decrease for the week, with a -7.88% drop in the past month and a -1.13% fall in the past quarter. The volatility ratio for the week is 15.28%, and the volatility levels for the past 30 days are at 14.18% for Phio Pharmaceuticals Corp The simple moving average for the past 20 days is -19.49% for PHIO’s stock, with a -51.30% simple moving average for the past 200 days.
Analysts’ Opinion of PHIO
Many brokerage firms have already submitted their reports for PHIO stocks, with H.C. Wainwright repeating the rating for PHIO by listing it as a “Buy.” The predicted price for PHIO in the upcoming period, according to H.C. Wainwright is $4 based on the research report published on August 05, 2020 of the previous year 2020.
PHIO Trading at -1.46% from the 50-Day Moving Average
After a stumble in the market that brought PHIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.81% of loss for the given period.
Volatility was left at 14.18%, however, over the last 30 days, the volatility rate increased by 15.28%, as shares sank -17.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.59% upper at present.
During the last 5 trading sessions, PHIO fell by -22.46%, which changed the moving average for the period of 200-days by -75.95% in comparison to the 20-day moving average, which settled at $0.9358. In addition, Phio Pharmaceuticals Corp saw 0.00% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHIO starting from Bitterman Robert J, who purchase 2,500 shares at the price of $0.91 back on Feb 26 ’24. After this action, Bitterman Robert J now owns 18,990 shares of Phio Pharmaceuticals Corp, valued at $2,275 using the latest closing price.
Bitterman Robert J, the President & CEO of Phio Pharmaceuticals Corp, purchase 1,000 shares at $2.84 during a trade that took place back on Jul 01 ’23, which means that Bitterman Robert J is holding 19,211 shares at $2,840 based on the most recent closing price.
Stock Fundamentals for PHIO
The total capital return value is set at -1.62. Equity return is now at value -112.46, with -92.08 for asset returns.
Based on Phio Pharmaceuticals Corp (PHIO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -158.34. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 85.73.
Currently, EBITDA for the company is -11.46 million with net debt to EBITDA at 0.72. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.01.
Conclusion
In conclusion, Phio Pharmaceuticals Corp (PHIO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
